Could NPDR Be Treated Orally?
Phase 1b results for danegaptide indicate promising safety profile in patients with non-proliferative diabetic retinopathy and macular edema
Clinical Scorecard: Could NPDR Be Treated Orally?
At a Glance
Category Detail
Condition Non-Proliferative Diabetic Retinopathy (NPDR) Key Mechanisms Stabilizes gap-junctions and protects against VEGF-induced down-regulation of TNFSF15. Target Population Patients with earlier stages of NPDR. Care Setting Clinical settings across the US, Germany, and the UK.
Key Highlights
Danegaptide is the first oral drug designed for diabetic retinopathy. Phase 1b trial showed good safety and tolerability results. More than half of study eyes showed reductions in vascular leakage. Statistically significant reduction in edema scores observed. Potential to reduce treatment burden compared to injection-based therapies. Guideline-Based Recommendations
Diagnosis
Assess retinal imaging for signs of NPDR and associated macular edema. Management
Consider danegaptide for patients with earlier stages of NPDR. Monitoring & Follow-up
Monitor for vascular leakage and edema scores during treatment. Risks
Evaluate the risk of progression to more advanced forms of diabetic retinopathy. Patient & Prescribing Data
Type 2 diabetic patients with NPDR.
Danegaptide could improve adherence and outcomes by providing an oral alternative to injections.
Clinical Best Practices
Utilize oral therapies to reduce patient burden and improve adherence. Monitor patient responses closely to optimize treatment regimens. References
